July 29, 2019
drug_delivery

Innovations in Drug Delivery System – Injectables

Since 2015, the global injectable/parenteral drug delivery market is growing at a compounded rate of 11.8% and is forecasted to reach $640 million by 2021. It has the potential to soon eclipse oral delivery as the primary route of administration of pharmaceuticals, driven by the increased use of biological drugs.1 […]
June 17, 2019
Rx Usage

Medicine Use and Spending in the USA

The latest report from the IQVIA™ Institute for Human Data Science presents the 2018 Medicines Use and Spending in the U.S. The report provides extensive metrics on drug usage and its cost to the US Healthcare system. We discuss some of the interesting findings of this report. 2018 witnessed a […]
July 17, 2017
clinical_dev_biosimilar

Ongoing Biosimilar Clinical Development in Oncology

As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute […]
June 19, 2017
Biosimilar dev in US and EU

Biosimilar Regulatory Development in US and EU

As per the 2015 IMS report, the global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020 [1]. This would translate to the biologics market potentially worth USD 390 billion in 2020. As many of the biologics will face patent expiration in the next 5 […]
June 5, 2017

India In The Global Biosimilar Play

In part 1 of this two part paper, we indicated that even as the western markets are opening up to mAb biosimilars, Indian biosimilar companies have focused on home turfs. In the absence of a crystal ball and presence of several caveats, there is no telling how the market will shape […]
June 1, 2017
Biosimilar The India Story

Biosimilars- The India Story

Conspicuous By Absence In US And EU The floodgates have opened for the first wave of the monoclonal antibody (mAb) biosimilars in the two most rewarding pharmaceutical markets US and EU. As several big pharmaceutical companies are gearing up for the opportunity, the Indian companies are conspicuous by their absence. […]